Market Overview:
The global tumor-specific antigen market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for early diagnosis and treatment of cancer, and technological advancements in tumor-specific antigen detection methods. Based on type, the global tumor-specific antigen market is segmented into coding region and non-coding region. The coding region segment is further divided into exons, introns, and promoters. The non-coding region segment includes microRNAs (miRNAs), long noncoding RNAs (lncRNAs), small nucleolar RNAs (snoRNAs), and ribosomal RNAs (rRNA). Based on application, the global tumor-specific antigen market is divided into drug discovery and development, diagnostics, clinical research laboratories/institutes/hospitals & clinics research laboratories/institutes/hospitals & clinics research laboratories/institutes/hospitals & clinics research laboratories/institutes&clinics), basic research institutes&basicresearchand others). Based on geography, the global tumor specific antigensmarketis segregatedinto North America,, Europe,, Asia Pacificand Middle East Africa ).
Product Definition:
A tumor-specific antigen is a protein or peptide on the surface of a cancer cell that is unique to that particular type of cancer. These antigens can be used to detect and diagnose tumors, and may also be targeted by therapeutic antibodies or vaccines.
Coding Region:
Coding region is the part of the genome which determines the protein sequence. The length of this region ranges from 7 to 21kb and it codes for around 200-300 amino acids. It is also known as open reading frame or long open reading frame (LORF). Coding regions are important in tumor-specific antigen market because they serve as a potential immunogen for cytotoxic T lymphocytes (CTLs) leading to antibody response against cancer cells.
Non-Coding Region:
Non-coding region is a part of the genome which does not contain genetic information for protein synthesis. Non-coding regions are involved in the control of cellular processes such as apoptosis, differentiation, proliferation & DNA replication. The non-coding region holds great potential in being used as a target for therapeutic interventions due to its role in regulating cell function and homeostasis.
The non-coding region is divided into introns.
Application Insights:
The drug discovery and development segment dominated the global tumor-specific antigen market in 2017. This can be attributed to the rising number of cancer drugs under clinical trials, which is expected to drive this segment over the forecast period. For instance, as per data published by WHO in 2018, around 70% of all oncology drugs are discovered through basic research and 30% through clinical trials. Thus, growing emphasis on R&D activities coupled with a rise in investment for such purposes is expected to fuel product demand over the forecast period.
On other hand, diagnostics held a significant share owing to increasing adoption of tumor-specific antigens for diagnosis of various cancers including lung cancer and breast cancer among others. Tumor-specific antigens are also used for immunotherapy wherein patients receive active or passive immunity against tumors using these molecules as an antigenic target for generating antibodies against them which can then be used therapeutically against cancers (Passos et al., 2016).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, continuous research activities for development of novel therapeutics and vaccines, and high adoption rate for advanced diagnostic techniques. The region is expected to maintain its dominance throughout the forecast period owing to increasing R&D investments by pharmaceutical companies as well as government support.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare spending by governments along with an increase in investment by private firms seeking potential revenue generation opportunities across this region. Moreover, growing awareness regarding early diagnosis coupled with rapidly improving healthcare infrastructure are some factors likely to boost regional market growth during the same period (2018-2030).
In addition, favorable regulatory policies adopted across various countries are also contributing toward industry expansion since they help reduce cost burden associated with clinical trials while maintaining high standards required for approval of new therapies & vaccines or other products developed from tumor-specific antigens.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for tumor-specific antigen market. According to World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths from the disease worldwide. This number is expected to increase to 21 million new cases and 13 million deaths by 2030. Thus, the increasing incidence of cancer is fueling the demand for tumor-specific antigen products and services thereby driving the growth of tumor-specific antigen market.
- Rising awareness about early diagnosis and treatment: There is a growing awareness among people about early diagnosis and treatment options for various types of cancers which is propelling the demand for tumor-specific antigen products and services thereby driving the growth of this market.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor-Specific Antigen Market Research Report
By Type
Coding Region, Non-Coding Region
By Application
Drug Discovery and Development, Diagnostics, Clinical and Basic Research, Others
By Companies
Agilent Technologies, Creative Diagnostics, Go Therapeutics, Lee Biosolutions, Bio-Rad, Biomrieux, Caris Life Sciences, Roche, Abcam, Merck Group, PerkinElmer, OriGene Technologies
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Tumor-Specific Antigen Market Report Segments:
The global Tumor-Specific Antigen market is segmented on the basis of:
Types
Coding Region, Non-Coding Region
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Drug Discovery and Development, Diagnostics, Clinical and Basic Research, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Agilent Technologies
- Creative Diagnostics
- Go Therapeutics
- Lee Biosolutions
- Bio-Rad
- Biomrieux
- Caris Life Sciences
- Roche
- Abcam
- Merck Group
- PerkinElmer
- OriGene Technologies
Highlights of The Tumor-Specific Antigen Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Coding Region
- Non-Coding Region
- By Application:
- Drug Discovery and Development
- Diagnostics
- Clinical and Basic Research
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor-Specific Antigen Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tumor-specific antigen is a protein found on the surface of cancer cells. This protein helps the cancer cells to evade immune system attack and grow more quickly.
Some of the major players in the tumor-specific antigen market are Agilent Technologies, Creative Diagnostics, Go Therapeutics, Lee Biosolutions, Bio-Rad, Biomrieux, Caris Life Sciences, Roche, Abcam, Merck Group, PerkinElmer, OriGene Technologies.
The tumor-specific antigen market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tumor-Specific Antigen Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tumor-Specific Antigen Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tumor-Specific Antigen Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tumor-Specific Antigen Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tumor-Specific Antigen Market Size & Forecast, 2018-2028
4.5.1 Tumor-Specific Antigen Market Size and Y-o-Y Growth
4.5.2 Tumor-Specific Antigen Market Absolute $ Opportunity
Chapter 5 Global Tumor-Specific Antigen Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tumor-Specific Antigen Market Size Forecast by Type
5.2.1 Coding Region
5.2.2 Non-Coding Region
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tumor-Specific Antigen Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tumor-Specific Antigen Market Size Forecast by Applications
6.2.1 Drug Discovery and Development
6.2.2 Diagnostics
6.2.3 Clinical and Basic Research
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tumor-Specific Antigen Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tumor-Specific Antigen Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tumor-Specific Antigen Analysis and Forecast
9.1 Introduction
9.2 North America Tumor-Specific Antigen Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tumor-Specific Antigen Market Size Forecast by Type
9.6.1 Coding Region
9.6.2 Non-Coding Region
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tumor-Specific Antigen Market Size Forecast by Applications
9.10.1 Drug Discovery and Development
9.10.2 Diagnostics
9.10.3 Clinical and Basic Research
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tumor-Specific Antigen Analysis and Forecast
10.1 Introduction
10.2 Europe Tumor-Specific Antigen Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tumor-Specific Antigen Market Size Forecast by Type
10.6.1 Coding Region
10.6.2 Non-Coding Region
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tumor-Specific Antigen Market Size Forecast by Applications
10.10.1 Drug Discovery and Development
10.10.2 Diagnostics
10.10.3 Clinical and Basic Research
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tumor-Specific Antigen Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tumor-Specific Antigen Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tumor-Specific Antigen Market Size Forecast by Type
11.6.1 Coding Region
11.6.2 Non-Coding Region
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tumor-Specific Antigen Market Size Forecast by Applications
11.10.1 Drug Discovery and Development
11.10.2 Diagnostics
11.10.3 Clinical and Basic Research
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tumor-Specific Antigen Analysis and Forecast
12.1 Introduction
12.2 Latin America Tumor-Specific Antigen Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tumor-Specific Antigen Market Size Forecast by Type
12.6.1 Coding Region
12.6.2 Non-Coding Region
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tumor-Specific Antigen Market Size Forecast by Applications
12.10.1 Drug Discovery and Development
12.10.2 Diagnostics
12.10.3 Clinical and Basic Research
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tumor-Specific Antigen Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tumor-Specific Antigen Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tumor-Specific Antigen Market Size Forecast by Type
13.6.1 Coding Region
13.6.2 Non-Coding Region
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tumor-Specific Antigen Market Size Forecast by Applications
13.10.1 Drug Discovery and Development
13.10.2 Diagnostics
13.10.3 Clinical and Basic Research
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tumor-Specific Antigen Market: Competitive Dashboard
14.2 Global Tumor-Specific Antigen Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Agilent Technologies
14.3.2 Creative Diagnostics
14.3.3 Go Therapeutics
14.3.4 Lee Biosolutions
14.3.5 Bio-Rad
14.3.6 Biomrieux
14.3.7 Caris Life Sciences
14.3.8 Roche
14.3.9 Abcam
14.3.10 Merck Group
14.3.11 PerkinElmer
14.3.12 OriGene Technologies
